BeiGene Dirección
Dirección controles de criterios 2/4
El CEO de BeiGene's es John Oyler , nombrado en Jan 2010, tiene una permanencia de 14.25 años. compensación anual total es $18.05M, compuesta por 4.4% salario y 95.6% primas, incluidas acciones y opciones de la empresa. posee directamente un 3.45% de las acciones de la empresa, por valor de $471.57M. La antigüedad media del equipo directivo y de la junta directiva es de 2.5 años y 4.3 años, respectivamente.
Información clave
John Oyler
Chief Executive Officer (CEO)
US$18.9m
Compensación total
Porcentaje del salario del CEO | 4.6% |
Permanencia del CEO | 14.3yrs |
Participación del CEO | 3.4% |
Permanencia media de la dirección | 2.6yrs |
Promedio de permanencia en la Junta Directiva | 4.3yrs |
Actualizaciones recientes de la dirección
Recent updates
Is BeiGene (NASDAQ:BGNE) Using Too Much Debt?
Apr 21BeiGene Still Bleeding Red Ink Despite Blockbuster Drug
Mar 08BeiGene, Ltd.'s (NASDAQ:BGNE) Intrinsic Value Is Potentially 26% Above Its Share Price
Jan 31Here's Why BeiGene (NASDAQ:BGNE) Can Manage Its Debt Despite Losing Money
Oct 16Is There An Opportunity With BeiGene, Ltd.'s (NASDAQ:BGNE) 39% Undervaluation?
Jul 11Rock star Growth Puts BeiGene (NASDAQ:BGNE) In A Position To Use Debt
Jun 19Revenues Not Telling The Story For BeiGene, Ltd. (NASDAQ:BGNE)
Apr 17A Look At The Fair Value Of BeiGene, Ltd. (NASDAQ:BGNE)
Mar 24Is BeiGene (NASDAQ:BGNE) Using Debt Sensibly?
Dec 07BeiGene upgraded to buy at Guggenheim on improved confidence in Brukinsa potential
Oct 13EMA panel recommends extending indication for BeiGene's cancer drug Brukinsa
Sep 16Análisis de compensación del CEO
Fecha | Compensación total | Salario | Ingresos de la empresa |
---|---|---|---|
Dec 31 2023 | US$19m | US$871k | -US$882m |
Sep 30 2023 | n/a | n/a | -US$959m |
Jun 30 2023 | n/a | n/a | -US$2b |
Mar 31 2023 | n/a | n/a | -US$2b |
Dec 31 2022 | US$18m | US$800k | -US$2b |
Sep 30 2022 | n/a | n/a | -US$2b |
Jun 30 2022 | n/a | n/a | -US$2b |
Mar 31 2022 | n/a | n/a | -US$2b |
Dec 31 2021 | US$17m | US$740k | -US$1b |
Sep 30 2021 | n/a | n/a | -US$1b |
Jun 30 2021 | n/a | n/a | -US$1b |
Mar 31 2021 | n/a | n/a | -US$1b |
Dec 31 2020 | US$14m | US$696k | -US$2b |
Sep 30 2020 | n/a | n/a | -US$2b |
Jun 30 2020 | n/a | n/a | -US$1b |
Mar 31 2020 | n/a | n/a | -US$1b |
Dec 31 2019 | US$13m | US$675k | -US$949m |
Sep 30 2019 | n/a | n/a | -US$829m |
Jun 30 2019 | n/a | n/a | -US$665m |
Mar 31 2019 | n/a | n/a | -US$737m |
Dec 31 2018 | US$28m | US$650k | -US$674m |
Sep 30 2018 | n/a | n/a | -US$505m |
Jun 30 2018 | n/a | n/a | -US$243m |
Mar 31 2018 | n/a | n/a | -US$147m |
Dec 31 2017 | US$10m | US$515k | -US$93m |
Compensación vs. Mercado: La compensación total de John($USD18.05M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD13.51M).
Compensación vs. Ingresos: La compensación de John ha aumentado mientras la empresa no es rentable.
CEO
John Oyler (55 yo)
14.3yrs
Permanencia
US$18,925,730
Compensación
Mr. John V. Oyler Co-Founded BeiGene, Ltd. and has been its Chief Executive Officer since 2010. Mr. Oyler Co-founded BioDuro, LLC and served as its Chief Executive Officer and President from 2005 to 2009....
Equipo directivo
Nombre | Posición | Permanencia | Compensación | Propiedad |
---|---|---|---|---|
Co-Founder | 14.3yrs | US$18.93m | 3.45% $ 554.6m | |
President & COO | 6yrs | US$11.00m | 0.060% $ 9.6m | |
Co-Chairman of Scientific Advisory Board & Non-Executive Director and Co-Founder | 14.3yrs | US$4.42m | 0.77% $ 124.1m | |
CFO & Principal Financial Officer | 2.9yrs | US$6.07m | 0.0055% $ 888.1k | |
General Counsel & Senior VP | 1.8yrs | US$4.05m | 0.0014% $ 222.0k | |
Global Head of R&D | no data | US$7.32m | 0.10% $ 16.3m | |
VP & Chief Accounting Officer | less than a year | sin datos | sin datos | |
Head of Investor Relations | no data | sin datos | sin datos | |
Chief Compliance Officer | less than a year | sin datos | sin datos | |
Senior VP & Head of Public Affairs - Greater China | 3.3yrs | sin datos | sin datos | |
Senior Vice President of Strategy & Corporate Development | 1.3yrs | sin datos | sin datos | |
Senior VP & Chief Medical Officer for Solid Tumors | 2.3yrs | sin datos | sin datos |
2.6yrs
Permanencia media
53.5yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de BGNE se considera experimentado (2.5 años antigüedad media).
Miembros de la Junta
Nombre | Posición | Permanencia | Compensación | Propiedad |
---|---|---|---|---|
Co-Founder | 13.6yrs | US$18.93m | 3.45% $ 554.6m | |
Co-Chairman of Scientific Advisory Board & Non-Executive Director and Co-Founder | 8.3yrs | US$4.42m | 0.77% $ 124.1m | |
Acting Head of Medicinal Chemistry & Member of Scientific Advisory Board | 3.1yrs | sin datos | sin datos | |
Independent Non-Executive Director & Member of the Scientific Advisory Committee | 9.1yrs | US$481.92k | 0.0025% $ 400.6k | |
Independent Non-Executive Director | 11.3yrs | US$480.80k | 0.20% $ 31.5m | |
Independent Non-Executive Director & Member of Scientific Advisory Committee | 3.8yrs | US$501.55k | 0.0013% $ 201.1k | |
Independent Non-Executive Director | 4.3yrs | US$513.15k | 0.00057% $ 91.7k | |
Co-Chairman of Scientific Advisory Committee & Independent Non-Executive Director | 2.3yrs | US$491.67k | 0.0012% $ 197.9k | |
Independent Non-Executive Director | less than a year | sin datos | 0% $ 0 | |
Independent Lead Director | 9.6yrs | US$487.05k | 0.0025% $ 400.6k | |
Member of Scientific Advisory Board & Independent Non-Executive Director | 2.3yrs | US$510.55k | 0.0012% $ 197.9k |
4.3yrs
Permanencia media
64yo
Promedio de edad
Junta con experiencia: La junta directiva de BGNE se considera experimentada (4.3 años de antigüedad promedio).